| Mr Daniel Evan Jossen, | |
|
1638 R St Nw, Washington, DC 20009-6446 | |
| (202) 618-0744 | |
| Not Available |
| Full Name | Mr Daniel Evan Jossen |
|---|---|
| Gender | Male |
| Speciality | Counselor - Mental Health |
| Location | 1638 R St Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013620418 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | (* (Not Available)) | Secondary |
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Daniel Evan Jossen, 2727 29th St Nw Apt 732, Washington, DC 20008-5551 Ph: (202) 657-3330 | Mr Daniel Evan Jossen, 1638 R St Nw, Washington, DC 20009-6446 Ph: (202) 618-0744 |
News Archive
In September 2009, Business Roundtable issued a report on health care cost trends prepared by Hewitt Associates. Its central finding was that, if present trends continue, the cost to provide an employee with health care will rise from $10,000 to $28,000 over ten years. Cost increases of this magnitude imperil the competitiveness of our companies and the health care coverage of our employees; they must be addressed.
Although the drug IFN-beta is commonly used to treat individuals with the relapsing-remitting form of multiple sclerosis (MS), little is known about the mechanism(s) by which it acts.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV (NYSE Euronext: PHARM) today announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema.
Ranbaxy Laboratories Limited (Ranbaxy) announced today that the U.S. District Court for the District of New Jersey hearing the preliminary injunction motion brought by Pfizer against Teva Pharmaceuticals USA, Inc. (Teva) and Ranbaxy Pharmaceuticals Inc. (RPI) enjoined Teva and RPI from selling RPI's quinapril tablets (5, 10, 20, and 40 mg).
› Verified 5 days ago
Ms. Cassaundra Janiece Wilkins, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3861 Alabama Ave Se, Washington, DC 20020 Phone: 202-645-4488 Fax: 202-645-4590 | |
Ms. Pauline Imbrigato, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 1012 14th St Nw, Suite 1025, Washington, DC 20005 Phone: 202-737-6000 Fax: 202-737-2332 | |
Giovanna Ysabela Dilauro, MS, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1110 Lamont St Nw, Washington, DC 20010 Phone: 407-731-4581 | |
Joseph Martinez-williams, Counselor Medicare: Not Enrolled in Medicare Practice Location: 101 Q St Ne, Washington, DC 20002 Phone: 202-674-2256 | |
Elyse Figueroa, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2812 Erie St Se Apt B34, Washington, DC 20020 Phone: 646-744-4458 | |
Melissa Cimino, LGPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 915 Rhode Island Ave Nw, Washington, DC 20001 Phone: 202-232-6810 | |
Lili Johnson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 441 21st St Ne, Washington, DC 20002 Phone: 202-341-6761 |